Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Cell | Jan 22, 2010

http://www.ncbi.nlm.nih.gov/pubmed/20141835

We describe a mechanism of tumorigenesis mediated by kinase-dead BRAF in the presence of oncogenic RAS. We show that drugs that selectively inhibit BRAF drive RAS-dependent BRAF binding to CRAF, CRAF activation, and MEK-ERK signaling. This does not occur when oncogenic BRAF is inhibited, demonstrating that BRAF inhibition per se does not drive pathway activation; it only occurs when BRAF is inhibited in the presence of oncogenic RAS. Kinase-dead BRAF mimics the effects of the BRAF-selective drugs and kinase-dead Braf and oncogenic Ras cooperate to induce melanoma in mice. Our data reveal another paradigm of BRAF-mediated signaling that promotes tumor progression. They highlight the importance of understanding pathway signaling in clinical practice and of genotyping tumors prior to administering BRAF-selective drugs, to identify patients who are likely to respond and also to identify patients who may experience adverse effects.

Pubmed ID: 20141835 RIS Download

Mesh terms: Animals | Antineoplastic Agents | Cell Line, Tumor | Humans | Melanoma | Mice | Mice, Transgenic | Proto-Oncogene Proteins B-raf | Proto-Oncogene Proteins c-raf | ras Proteins

Research resources used in this publication

None found

Research tools detected in this publication

Data used in this publication

None found

Associated grants

  • Agency: Wellcome Trust, Id: 080333/Z/06/Z
  • Agency: Cancer Research UK, Id: 10433
  • Agency: Cancer Research UK, Id: 10437
  • Agency: Cancer Research UK, Id: 13083
  • Agency: Cancer Research UK, Id: C107/A10433

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.